Tonix Pharmaceuticals Files 8-K

Ticker: TNXP · Form: 8-K · Filed: Jul 16, 2025 · CIK: 1430306

Sentiment: neutral

Topics: corporate-filing, 8-K

Related Tickers: TNXP

TL;DR

TNXP filed an 8-K on 7/16/25, standard corporate update.

AI Summary

Tonix Pharmaceuticals Holding Corp. filed an 8-K on July 16, 2025, reporting on other events and financial statements. The filing details the company's corporate structure, including its incorporation in Nevada and its principal executive offices located at 26 Main Street, Chatham, New Jersey.

Why It Matters

This filing provides an update on Tonix Pharmaceuticals' corporate and financial reporting, which is crucial for investors to stay informed about the company's status and regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new financial or operational information that would immediately impact risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Tonix Pharmaceuticals Holding Corp.?

The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of July 16, 2025.

In which state is Tonix Pharmaceuticals Holding Corp. incorporated?

Tonix Pharmaceuticals Holding Corp. is incorporated in Nevada.

What is the address of Tonix Pharmaceuticals Holding Corp.'s principal executive offices?

The address of Tonix Pharmaceuticals Holding Corp.'s principal executive offices is 26 Main Street, Chatham, New Jersey, 07928.

What is the Commission File Number for Tonix Pharmaceuticals Holding Corp.?

The Commission File Number for Tonix Pharmaceuticals Holding Corp. is 001-36019.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on July 16, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 16, 2025 regarding Tonix Pharmaceuticals Holding Corp. (TNXP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing